Anika Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Anika Therapeutics

13/03/2024 21:01

* Anika Therapeutics Inc  ANIK.OQ  reported a quarterly
adjusted
loss of $4.30​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -34 cents.  The mean expectation of three analysts for
the quarter was for a loss of 26 cents per share. Wall Street
expected results to range from -32 cents to -21 cents per share.
    * Revenue rose 8.5% to $42.97 million from a year ago;
analysts
expected $41.40 million. 
    * Anika Therapeutics Inc's reported EPS for the quarter was
a loss
of $4.30​.
    * The company reported a quarterly loss of $63 million.
    * Anika Therapeutics Inc shares had risen by 13.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Anika
Therapeutics Inc is $29.00 
This summary was machine generated from LSEG data March 13 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.26          -4.30          Missed
 Sep. 30 2023      -0.37          -0.45          Missed
 Jun. 30 2023      -0.27          -0.19          Beat
 Mar. 31 2023      -0.30          -0.47          Missed